To explore the efficacy of Glofitamab in sequential treatment strategies for relapsed/refractory B-cell lymphoma in a real-world setting.
Approach:
Study Design: A single-center retrospective cohort analysis of 24 patients with relapsed/refractory B-cell lymphoma, categorized into three treatment groups.
Patient Groups: Group 1: Glofitamab as rescue therapy after CAR-T failure; Group 2: Glofitamab bridging to CAR-T therapy; Group 3: Glofitamab monotherapy.
Treatment Protocol: Patients received Glofitamab following a step-up dosing regimen, with initial doses followed by a fixed dose every three weeks.
Key Findings:
Glofitamab demonstrated controllable safety and durable anti-tumor activity across all treatment scenarios.
Clinical benefits were observed even after CAR-T therapy failure.
Interpretation:
Glofitamab may serve as an effective treatment option in various sequential treatment strategies for relapsed/refractory B-cell lymphoma.
Limitations:
Single-center study with a small sample size of 24 patients.
Retrospective design may introduce bias.
Conclusion:
Glofitamab shows promise in managing relapsed/refractory B-cell lymphoma, particularly after CAR-T therapy failure.
